A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.

Journal: Canadian journal of diabetes
PMID: 35181219

Abstract

OBJECTIVES: In recent clinical studies, saxagliptin exhibited nephroprotective potential by lowering albuminuria. In this study, we aimed to determine whether these kidney effects of saxagliptin were mediated by changes in markers of kidney tubular damage, including urinary neutrophil gelatinase-associated protein (uNGAL) and liver-type fatty acid-binding protein (uL-FABP).

Authors

  • Marwa Mohsen
    Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt. Electronic address: marwa.mohseneldawy90@gmail.com.
  • Ahmed A Elberry
    Faculty of Medicine, Clinical Pharmacology Department, Beni-Suef University, Beni-Suef, Egypt.
  • Alaa Mohamed Rabea
    Faculty of Medicine, Internal Medicine and Nephrology Department, Beni-Suef University, Beni-Suef, Egypt.
  • Doaa Mahmoud Khalil
    Faculty of Medicine, Public Health and Community Medicine Department, Beni-Suef University, Beni-Suef, Egypt.
  • Mohamed E A Abdelrahim
    Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt.
  • Raghda R S Hussein
    Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt; Clinical Pharmacy Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.

Keywords

External Resources

Popular Topics
Recent Journals